Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease
- PMID: 20733102
- DOI: 10.1161/CIRCULATIONAHA.109.911669
Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease
Abstract
Background: This study compared the 10-year follow-up of percutaneous coronary intervention (PCI), coronary artery surgery (CABG), and medical treatment (MT) in patients with multivessel coronary artery disease, stable angina, and preserved ventricular function.
Methods and results: The primary end points were overall mortality, Q-wave myocardial infarction, or refractory angina that required revascularization. All data were analyzed according to the intention-to-treat principle. At a single institution, 611 patients were randomly assigned to CABG (n=203), PCI (n=205), or MT (n=203). The 10-year survival rates were 74.9% with CABG, 75.1% with PCI, and 69% with MT (P=0.089). The 10-year rates of myocardial infarction were 10.3% with CABG, 13.3% with PCI, and 20.7% with MT (P<0.010). The 10-year rates of additional revascularizations were 7.4% with CABG, 41.9% with PCI, and 39.4% with MT (P<0.001). Relative to the composite end point, Cox regression analysis showed a higher incidence of primary events in MT than in CABG (hazard ratio 2.35, 95% confidence interval 1.78 to 3.11) and in PCI than in CABG (hazard ratio 1.85, 95% confidence interval 1.39 to 2.47). Furthermore, 10-year rates of freedom from angina were 64% with CABG, 59% with PCI, and 43% with MT (P<0.001).
Conclusions: Compared with CABG, MT was associated with a significantly higher incidence of subsequent myocardial infarction, a higher rate of additional revascularization, a higher incidence of cardiac death, and consequently a 2.29-fold increased risk of combined events. PCI was associated with an increased need for further revascularization, a higher incidence of myocardial infarction, and a 1.46-fold increased risk of combined events compared with CABG. Additionally, CABG was better than MT at eliminating anginal symptoms. Clinical Trial Registration Information- URL: http://www.controlled-trials.com.
Registration number: ISRCTN66068876.
Comment in
-
Is optimal medical therapy "optimal therapy" for multivessel coronary artery disease? Optimal management of multivessel coronary artery disease.Circulation. 2010 Sep 7;122(10):943-5. doi: 10.1161/CIRCULATIONAHA.110.969980. Epub 2010 Aug 23. Circulation. 2010. PMID: 20733095 No abstract available.
-
Coronary artery surgery for multivessel coronary artery disease reduces 10-year risk of myocardial infarction compared with medical treatment or percutaneous coronary intervention.Evid Based Med. 2011 Apr;16(2):50-1. doi: 10.1136/ebm1162. Epub 2011 Jan 11. Evid Based Med. 2011. PMID: 21224282 No abstract available.
Similar articles
-
Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.Circulation. 2007 Mar 6;115(9):1082-9. doi: 10.1161/CIRCULATIONAHA.106.625475. Circulation. 2007. PMID: 17339566 Clinical Trial.
-
Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.J Thorac Cardiovasc Surg. 2013 Nov;146(5):1105-12. doi: 10.1016/j.jtcvs.2012.08.015. Epub 2012 Aug 31. J Thorac Cardiovasc Surg. 2013. PMID: 22944095 Clinical Trial.
-
The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results.J Am Coll Cardiol. 2004 May 19;43(10):1743-51. doi: 10.1016/j.jacc.2003.08.065. J Am Coll Cardiol. 2004. PMID: 15145093 Clinical Trial.
-
Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery.JACC Cardiovasc Interv. 2008 Oct;1(5):483-91. doi: 10.1016/j.jcin.2008.07.001. JACC Cardiovasc Interv. 2008. PMID: 19463349 Review.
-
Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery.Minerva Cardioangiol. 2003 Oct;51(5):585-97. Minerva Cardioangiol. 2003. PMID: 14551526 Review.
Cited by
-
Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis.JAMA Intern Med. 2020 Dec 1;180(12):1638-1646. doi: 10.1001/jamainternmed.2020.4748. JAMA Intern Med. 2020. PMID: 33044497 Free PMC article.
-
Effectiveness of Clinical, Surgical and Percutaneous Treatment to Prevent Cardiovascular Events in Patients Referred for Elective Coronary Angiography: An Observational Study.Vasc Health Risk Manag. 2020 Jul 16;16:285-297. doi: 10.2147/VHRM.S246963. eCollection 2020. Vasc Health Risk Manag. 2020. PMID: 32764949 Free PMC article.
-
Five-year outcomes in patients with multivessel coronary artery disease undergoing surgery or percutaneous intervention.Sci Rep. 2024 Feb 8;14(1):3218. doi: 10.1038/s41598-024-53905-4. Sci Rep. 2024. PMID: 38332036 Free PMC article.
-
Invasive therapy versus conservative therapy for patients with stable coronary artery disease: An updated meta-analysis.Clin Cardiol. 2021 May;44(5):675-682. doi: 10.1002/clc.23592. Epub 2021 Mar 20. Clin Cardiol. 2021. PMID: 33742721 Free PMC article.
-
Conservative strategy for treatment of stable coronary artery disease.World J Clin Cases. 2015 Feb 16;3(2):163-70. doi: 10.12998/wjcc.v3.i2.163. World J Clin Cases. 2015. PMID: 25685763 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous